Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 10:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,260 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Part 2: Placebo Clear all
Completed Phase 3 Interventional Results available

An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)

NCT02623699
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Tofersen, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
20
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers

NCT03060447
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Vesatolimod, Placebo, ART
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Ft. Pierce, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

NCT04772885
View directory record Official record
Conditions
Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Interventions
KT-474/Placebo, KT-474
Drug
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
14
States / cities
Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2022 · Synced Sep 10, 2026, 10:55 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis

NCT02466243
View directory record Official record
Conditions
Dermatomyositis
Interventions
JBT-101, Placebo
Drug
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

NCT01821833
View directory record Official record
Conditions
Breast Cancer, Ovarian Neoplasm, Pain
Interventions
Omega-3 fatty acid, Placebo, Paclitaxel
Dietary Supplement · Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants

NCT04223349
View directory record Official record
Conditions
Healthy
Interventions
JNJ-70033093, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 10, 2026, 10:55 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

NS-050/NCNP-03 in Boys With DMD (Meteor50)

NCT06053814
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
NS-050/NCNP-03, Placebo
Drug
Lead sponsor
NS Pharma, Inc.
Industry
Eligibility
4 Years to 15 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

A Study of Gantenerumab in Participants With Mild Alzheimer Disease

NCT02051608
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Gantenerumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
30
States / cities
Sun City, Arizona • Tucson, Arizona • Costa Mesa, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 10, 2026, 10:55 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

NCT05403385
View directory record Official record
Conditions
Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
Interventions
inupadenant, Placebo, Carboplatin, Pemetrexed
Drug
Lead sponsor
iTeos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Fayetteville, Arkansas • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Phase 1 Interventional

Treatment of Supine Hypertension in Autonomic Failure

NCT00223717
View directory record Official record
Conditions
Hypertension
Interventions
Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress
Drug · Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Phase 1Phase 2 Interventional

Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

NCT05440643
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut SLIT-tablet, Placebo
Biological · Other
Lead sponsor
ALK-Abelló A/S
Industry
Eligibility
4 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
33
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects

NCT01696604
View directory record Official record
Conditions
Cachexia
Interventions
GSK2849466, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

NCT01218204
View directory record Official record
Conditions
Dyslipidaemias, Dyslipidemias
Interventions
10mg atorvastatin, 80mg atorvastatin, GSK1292263 Placebo, 100mg GSK1292263, 300mg GSK1292263, 800mg GSK1292263, 10mg ezetimibe, Washout
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
21
States / cities
Anniston, Alabama • Chula Vista, California • Stockton, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants

NCT04988152
View directory record Official record
Conditions
Covid19
Interventions
sotrovimab, Placebo to Biologic
Biological · Other
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Anaheim, California • Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

NCT05631704
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Midazolam, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder

NCT02066792
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
D-Cycloserine, Placebo, Cognitive Behavioral Therapy
Drug · Behavioral
Lead sponsor
Jasper A. Smits
Other
Eligibility
18 Years to 70 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 10, 2026, 10:55 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

NCT06299098
View directory record Official record
Conditions
Obesity
Interventions
Trevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab, Semaglutide, Matching Placebo-Part A, Matching Placebo-Trevogrumab, Matching Placebo-Garetosmab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,005 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
58
States / cities
Anniston, Alabama • Cullman, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

NCT03432884
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BGB-3111, Placebo, Moxifloxacin
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Not applicable Interventional Results available

Quetiapine for the Reduction of Cocaine Use

NCT00631748
View directory record Official record
Conditions
Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Drug Abuse, Substance Abuse
Interventions
quetiapine fumarate, Matched Placebo, Cognitive-behavioral Therapy
Drug · Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation

NCT00909727
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Sep 10, 2026, 10:55 AM EDT
Terminated Phase 1 Interventional Results available

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

NCT01483183
View directory record Official record
Conditions
Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Interventions
OPC-108459, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Hollywood, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Results available

Advancing Personalized Antidepressant Treatment Using PET/MRI

NCT02623205
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Sep 10, 2026, 10:55 AM EDT
Recruiting Phase 2 Interventional

Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease

NCT07682896
View directory record Official record
Conditions
Graves' Disease
Interventions
Experimental: YB-101, Placebo YB-101
Drug
Lead sponsor
Yarrow Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
28
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Tolerability Study of RJX Drug Product in Healthy Participants

NCT03680105
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
RJX, Placebo
Drug
Lead sponsor
Reven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Sep 10, 2026, 10:55 AM EDT